Clinical efficacy of hyperthermic intraperitoneal chemotherapy on the malignant ascites in gastric cancer patients following the preoperative radiotherapy

Background: to investigate the clinical efficacy of hyperthermic intraperitoneal chemotherapy in combination with the malignant ascites in gastric cancer following the intensive preoperative radiotherapy for radical surgery of tumor. materials and methods: we selected a total of 112 gastric cancer patients who had been operated on for radical surgery of tumor in this hospital as subjects that were randomized into the control group and the observation group, with 56 patients in each group. patients in the control group took the abdominal aspiration in combination with the intravenous chemotherapy, while those in the observation group underwent the hyperthermic intraperitoneal chemotherapy. after treatment, we compared the effectiveness rate, levels of tumor markers, incidence rates of adverse reactions, and karnofsky (kps) scores between the two groups. results: in the observation group and the control group, the effectiveness rates of patients were 71.43% and 44.64%, showing the statistical significance of the difference (p < 0.05); after treatment, the levels of cea, ca125, and ca199, tumor markers, were decreased compared to before treatment (p < 0.05). the incidence rates of adverse reactions were 75.00% and 82.14%, showing no statistical significance of difference (p > 0.05). following the treatment, the kps scores were improved in two groups compared to before treatment (p < 0.05). conclusion: for gastric cancer patients with malignant ascites, hyperthermic intraperitoneal chemotherapy excels in the clinical efficacy by decreasing the level of tumor markers, to improve the life quality of patients, but with no increase in the incidence rate of adverse reactions.